Kuo et al. reported that pharmacological and genetic inactivation of NPY2R led to a reduction in adipogenesis and abdominal obesity, providing support for NPY-NPYR-based drugs as candidate anti-obesity-therapeutics (36). Here, NPY2R is linked to obesity due to melanocortin 4 receptor deficiency.